Andrew Witty, chief executive of UK-headquartered drug major GlaxoSmithKline, has set out - in a speech titled Big Pharma a Catalyst for Change - an ambitious new agenda to tackle the challenges of improving global public health. Speaking at the Harvard Medical School in Massachusetts, USA, Mr Witty described the task facing the world's second-largest pharmaceutical firm by prescription sales as "huge." He said: "Africa, for example, has 34 of the 50 poorest countries in the world and suffers 24% of the global disease burden."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze